QuidelOrtho Corporation (QDEL)

SEC filings show no going-concern warning and covenant compliance, but profitability remains weak. FY2025 revenue was $2.73B (-2% YoY) and Q1'26 revenue fell to $619.8M (-11% YoY); TTM net margin is -45.57% with ROIC -19.88%. Leverage is heavy (total debt ~$2.83B) and risk signals are poor (Altman Z -0.17; interest coverage -5.25). While EV/Sales is ~1.37x, free cash flow is negative (FCF yield -8.25%) and DCF estimates conflict; analyst consensus target ($12.25) is below the current share price ($13.38).

Last ~14d media tone is mildly positive but very thin, driven mainly by the announced (non-material) CFO appointment, and it screens slightly better than the 30–90d baseline that was mixed/near-neutral around Q1 execution/guidance concerns and the LEX acquisition. No clear actionable 1–30d catalysts surfaced, retail sentiment is indeterminate due to Reddit 429 limits, and the legal/regulatory screen is clean—leaving a forming/absent short-term setup.

On the latest trading day QDEL closed 13.47, reclaiming EMA9, EMA21, WMA21, SMA50 and daily VWAP after the June pullback, which improves the near-term tone. The counterweights are that the stock still sits just under SMA20 and far below SMA200, while MACD is only 0.01 and remains under its 0.17 signal; ADX14 at 45.44 shows strong trend conditions but not a clean bullish trend by itself. Liquidity and event checks pass, yet the strategy still blocks a new long because fundamentalScore is 2.